Quantum BioPharma

Most approved MS therapies are designed to modulate or suppress the immune system.

But the immune system may not be the whole story.

For decades, MS treatment has largely focused on reducing immune-driven attacks. Quantum BioPharma
$QNTM
is exploring a different scientific question: whether MS also involves neurodegenerative mechanisms tied directly to myelin damage.

This is the demyelination pathway.

Lucid-MS, also known as LUCID-21-302, is being developed as a non-immunomodulatory investigational new chemical entity designed to target PAD2 an enzyme involved in abnormal myelin protein citrullination, a process believed to increase myelin vulnerability in MS.

In preclinical animal models, Lucid-MS demonstrated signals supporting further research into this mechanism.

Rather than targeting the immune system, Lucid-MS is focused on the biology of demyelination itself.

A different mechanism. A different pathway. A different approach to MS research. No Drugs currently on the market that are approved do what Lucid-MS is designed to do.

Lucid-MS is a Investigational drug candidate. Not approved by the FDA or Health Canada. Currently in clinical development.

Stories like Diana Harrington’s remind us why MS awareness matters.

Behind every diagnosis is a person, a family, and often a caregiver offering daily love, patience, and support.

Quantum BioPharma is honoured to help raise awareness for the Multiple Sclerosis community. Thank you to the National MS Society for sharing Diana’s story and highlighting the strength of those living with MS and the families who stand beside them.